| Literature DB >> 32493843 |
Yuan Liu1,2, Travis B Lear1,3, Manish Verma4, Kent Zq Wang4, P Anthony Otero4, Alison C McKelvey1, Sarah R Dunn1, Erin Steer4, Nicholas W Bateman5, Christine Wu5, Yu Jiang6, Nathaniel M Weathington1, Mauricio Rojas1, Charleen T Chu2,4,7,8, Bill B Chen1,9, Rama K Mallampalli1,5,10.
Abstract
Mitochondrial quality control is mediated by the PTEN-induced kinase 1 (PINK1), a cytoprotective protein that is dysregulated in inflammatory lung injury and neurodegenerative diseases. Here, we show that a ubiquitin E3 ligase receptor component, FBXO7, targets PINK1 for its cellular disposal. FBXO7, by mediating PINK1 ubiquitylation and degradation, was sufficient to induce mitochondrial injury and inflammation in experimental pneumonia. A computational simulation-based screen led to the identification of a small molecule, BC1464, which abrogated FBXO7 and PINK1 association, leading to increased cellular PINK1 concentrations and activities, and limiting mitochondrial damage. BC1464 exerted antiinflammatory activity in human tissue explants and murine lung inflammation models. Furthermore, BC1464 conferred neuroprotection in primary cortical neurons, human neuroblastoma cells, and patient-derived cells in several culture models of Parkinson's disease. The data highlight a unique opportunity to use small molecule antagonists that disrupt PINK1 interaction with the ubiquitin apparatus to enhance mitochondrial quality, limit inflammatory injury, and maintain neuronal viability.Entities:
Keywords: Cell stress; Drug therapy; Neuroscience; Parkinson’s disease
Mesh:
Substances:
Year: 2020 PMID: 32493843 PMCID: PMC7308049 DOI: 10.1172/jci.insight.131834
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708